Technical Analysis for BLCM - Bellicum Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
F 2.93 -7.86% -0.25
BLCM closed down 7.86 percent on Tuesday, April 20, 2021, on 40 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
Earnings due: May 5
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical BLCM trend table...

Date Alert Name Type % Chg
180 Bearish Setup Bearish Swing Setup 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Wide Bands Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Lizard Bullish Bullish Day Trade Setup -7.86%
Doji - Bullish? Reversal -7.86%
Older End-of-Day Signals for BLCM ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Fell Below Previous Day's Low about 12 hours ago
Down 5% about 13 hours ago
Fell Below Lower Bollinger Band about 13 hours ago
60 Minute Opening Range Breakdown about 14 hours ago
Down 3% about 14 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Bellicum Pharmaceuticals, Inc. Description

Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of various forms of cancer. Its lead clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation. The company is also developing BPX-201, a dendritic cell cancer vaccine, which is in a Phase I clinical trial for the treatment of metastatic castrate-resistant prostate cancer. Its preclinical product candidates include BPX-401, a chimeric antigen receptor (CAR-T) product candidate for the treatment of hematological cancers that express the CD19 antigen; BPX-601, a CAR-T product candidate for treating solid tumors overexpressing the prostate stem cell antigen; and BPX-701, a TCR product candidate for the treatment of solid tumors expressing the preferentially-expressed antigen in melanoma. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Solid Tumors Immunotherapy Cancer Treatments Prostate Cancer Virotherapy Melanoma Immunotherapies Vaccination Cell Therapy Transplantation Hematopoietic Stem Cell Chimeric Antigen Receptor Cancer Vaccine Resistant Prostate Cancer Dendritic Cell Hematological Cancers Treatment Of Hematological Cancers Treatment Of Various Forms Of Cancer

Is BLCM a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 9.56
52 Week Low 2.62
Average Volume 522,778
200-Day Moving Average 4.99
50-Day Moving Average 4.28
20-Day Moving Average 3.56
10-Day Moving Average 3.38
Average True Range 0.33
ADX 18.84
+DI 16.12
-DI 29.73
Chandelier Exit (Long, 3 ATRs ) 3.48
Chandelier Exit (Short, 3 ATRs ) 3.88
Upper Bollinger Band 4.10
Lower Bollinger Band 3.01
Percent B (%b) -0.08
BandWidth 30.46
MACD Line -0.27
MACD Signal Line -0.24
MACD Histogram -0.0363
Fundamentals Value
Market Cap 17.87 Million
Num Shares 6.1 Million
EPS -2.31
Price-to-Earnings (P/E) Ratio -1.27
Price-to-Sales 3.00
Price-to-Book 40.34
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.37
Resistance 3 (R3) 3.40 3.30 3.29
Resistance 2 (R2) 3.30 3.19 3.28 3.27
Resistance 1 (R1) 3.11 3.12 3.06 3.08 3.24
Pivot Point 3.01 3.01 2.98 2.99 3.01
Support 1 (S1) 2.82 2.90 2.77 2.79 2.62
Support 2 (S2) 2.72 2.83 2.70 2.59
Support 3 (S3) 2.53 2.72 2.57
Support 4 (S4) 2.50